arrow
I

Ian Poulton

university of oxford
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection

重复受控人体疟疾感染后对 *Plasmodium vivax* 的临床免疫发展

2025-09-250
OAAI
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial

英国成人中二价埃博拉病毒和苏丹病毒ChAdOx1载体疫苗的安全性及免疫原性:一项开放标签、非随机、首次人体、1期临床试验

2025-02-010
OAAI
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
2023-08-0110
OAAI
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
2023-07-1216
OAAI
Tolerability and immunogenicity of an intranasally- administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
2022-11-0182
OAAI
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics
2022-08-226
OAAI
Controlled human malaria infection with a clone of Plasmodium vivax with high- quality genome assembly
2021-12-0817
OA
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
2021-07-3035
OAAI
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

ChAd63/MVA Pfs25-IMX313在第一阶段人体试验中的安全性和免疫原性

2021-07-1426
OAAI
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

RH5疫苗接种后人类血液阶段疟疾生长和免疫相关性降低

MED
IF11.8
2021-06-0185
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020-12-17454
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020-12-17233
OAAI
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
2020-07-01166
OAAI
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
2020-06-2528
OAAI